Key Performance Indicators
Bioavailability
64%
Range: 61%–64%
Subcutaneous absorption
Max Clearance Time
13
Weeks (300 mg QW dosing)
Time to non-detectable conc.
PRIMARY
Injection Site Rxn
38%
Upper limit frequency
Most common AE
PRIMARY
EoE Maint. Dose
1200
mg per month (300mg QW)
Highest intensity indication
1
Adverse Reaction Profile: Local vs. Systemic
Injection-site reactions are the most frequent adverse event, followed by respiratory infections and immunogenicity.
2
Monthly Maintenance Dose Intensity by Indication
Eosinophilic Esophagitis (EoE) requires weekly dosing, resulting in double the monthly drug exposure compared to Asthma or Atopic Dermatitis.
3
Pharmacokinetic Clearance Time by Regimen
Drug clearance is frequency-dependent; weekly dosing extends the washout period to 13 weeks compared to 9 weeks for lower-frequency dosing.
4
Pediatric Dose Escalation by Weight (Atopic Dermatitis)
Dosing follows a step-wise linear increase based on weight tiers, ranging from 200mg to 600mg monthly equivalents.
5
Ocular Adverse Event Spectrum
While conjunctivitis can affect up to 10% of patients, severe ocular complications like keratitis are rare (<1%).
Editorial Conclusion
“Dupilumab offers a versatile therapeutic option with a predictable safety profile, though dosing complexity increases significantly for Eosinophilic Esophagitis compared to respiratory and dermatologic indications.”
EoE requires 300mg weekly dosing, double the maintenance load of severe asthma.
Injection-site reactions (up to 38%) and conjunctivitis (up to 10%) are the primary safety monitoring parameters.
Clearance times vary by ~4 weeks depending on the dosing frequency chosen.
Clinical Implication
Clinicians must carefully distinguish between indication-specific dosing regimens and monitor ocular symptoms, particularly in patients with a history of allergic conjunctivitis.
Reference Data & Sources
Complete Data Table
| Metric | Group | Value | Unit | Source |
|---|---|---|---|---|
| Volume of Distribution | Adults | 4.8 ± 1.3 L | L | Pharmacokinetics |
| Bioavailability | Adults | 61% to 64% | % | Pharmacokinetics |
Abbreviations
EoE = Eosinophilic Esophagitis · AD = Atopic Dermatitis · QW = Once Weekly · Q2W = Every 2 Weeks · Q4W = Every 4 Weeks
Source
UpToDate, Inc. (2024). Dupilumab: Drug information.
Limitations
Adverse reaction rates are aggregated from labeling and may not reflect real-world evidence for all subgroups. Specific N values for safety populations were not provided in the source text.